Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study finds benefits, less organ rejection using immunosuppressive combination for heart transplants

23.05.2005


Amid the debate over which combination of immunosuppressive agents works best in helping patients fight off rejection of their new heart after transplant surgery, a new study led by researchers at the UCLA Heart Transplant Program showed that one particular combination using tacrolimus (TAC or PrografÒ) had significant anti-rejection benefits for heart transplant patients over other combinations.



A mix of immunosuppressive therapies is typically used to prevent a recipient’s body from rejecting a transplanted organ. Rejection is one of the most common causes of death in the first year after heart transplantation.

"Until now, there has been a lack of definitive clinical trial data comparing commonly used immunosuppressive agents, and this has caused some debate over what is the most advantageous combination therapies for heart transplant recipients," said Dr. Jon Kobashigawa, lead author of the study and medical director of the UCLA Heart Transplant Program. "We now have results that demonstrate benefits in treating non-cellular and humoral rejection and this is significant step forward for heart transplant patients."


The study results, presented at the 6th American Transplant Congress in Seattle, involved more than 340 heart transplant recipients, and evaluated three combination therapies: 1) TAC + mycophenolate mofetil (MMF) and steroids, 2) cyclosporine microemulsion (CYA) + MMF and steroids, and 3) TAC + sirolimus (SRL) and steroids.

The primary purpose of this study was to compare the incidence of rejection requiring treatment, as measured by the International Society for Heart and Lung Transplantation (ISHLT) grading system.

Humoral rejection has been recently described in liver, kidney and heart transplant recipients by the National Institutes of Health (NIH) Consensus Conference. Humoral rejection is caused by the body making antibodies that can attack the donor organ, which is similar to the way that antibodies attack other foreign objects such as viruses or other infectious agents. This form of rejection can occur immediately (hyperacute rejection), or later after transplantation. The antibodies are either preformed antibodies (causing hyperacute rejection) or represent antibodies against the donor organ that developed after transplantation.

In heart transplant recipients, humoral rejection has been reported to play a role in the donor heart becoming weak in the early post-transplant period, and to be a risk factor for the development of transplant coronary artery disease, which is one of the major factors limiting long-term survival.

The study found no significant differences between treatment groups in survival or incidence of treated cellular rejection. Importantly, there was a significant reduction in any treated rejection in the TAC-treated groups. The category of any treated rejection included both cellular and humoral rejection. Therefore, these results suggested less humoral rejection in the TAC-treated groups.

The study also found that the TAC/MMF group had significantly better kidney function and lower triglycerides levels compared to the other two groups. Rates of post transplant diabetes were not significantly different. Fewer viral infections, but more fungal infections, were found in the TAC/SRL group.

The authors concluded that in heart transplant patients, TAC/MMF appeared to offer more advantages than either TAC/SRL or CYA/MMF, including the lowest incidence of any treated rejection and an improved side effect profile.

Other study authors included Dr. Leslie W. Miller, University of Minnesota, Minneapolis, MN; Dr. Stuart D. Russell, Johns Hopkins Hospital, Baltimore, MD; Dr. Gregory A. Ewald, Washington University, St. Louis, MO; Dr. Mark J. Zucker, Beth Israel Hospital, Newark, NJ; Dr. L. R. Goldberg, University of Pennsylvania, Philadelphia, PA; Dr. H. J. Eisen, Drexel University, Philadelphia, PA; Kim Salm, RN, D. Tolzman, W. E. Fitzsimmons, PharmD and Dr. M.R. First, Fujisawa Healthcare, Inc., Deerfield, IL; Dr. J. Gao, The EMMES Corporation, Rockville, MD.

Amy Waddell | EurekAlert!
Further information:
http://www.mednet.ucla.edu

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>